A Phase 2 interventional study of MAP0010 low dose and MAP0010 high dose in Asthma, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2014-01-09.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 46th largest by enrollment of the 108 interventional ones that give a count, is one of 8 that started in 2006, is one of 5 in phase 2, and was the 55th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 208 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
11 studies in Asthma by AbbVie: none open now, 1 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Asthma by AbbVie, this one is the 3rd largest by enrollment, is one of 3 that started in 2006, is one of 6 in phase 2, and was the 6th registered.
AbbVie’s Asthma studies by the year they started, since 2005.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 11 in Asthma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
Drug: MAP0010 low dose
a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
Drug: MAP0010 high dose
Placebo delivered by nebulization twice daily for 6 weeks
Drug: Placebo
a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
Placebo delivered by nebulization twice daily for 6 weeks
Change From Baseline in Daytime Composite Symptom Score
The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 5 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.
Time frame: baseline, week 6
Change From Baseline in Nighttime Composite Symptom Score
The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 5 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.
Time frame: baseline, week 6
Change From Baseline in FEV1% Predicted
The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer. An increase indicates an improvement (a greater volume of air expired).
Time frame: baseline, week 6
| Milestone | MAP0010 High Dose | MAP0010 Low Dose | Placebo |
|---|---|---|---|
| Started | 69 | 70 | 69 |
| Completed | 57 | 58 | 45 |
| Not completed | 12 | 12 | 24 |
The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 5 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.
| units on a scale | MAP0010 High Dose | MAP0010 Low Dose | Placebo |
|---|---|---|---|
| Baseline | 3.1 ± 1.90 | 2.8 ± 1.75 | 2.6 ± 1.59 |
| Change from Baseline at week 6 | -0.7 ± 1.80 | -1.4 ± 1.48 | -0.6 ± 1.63 |
The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 5 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.
| units on a scale | MAP0010 High Dose | MAP0010 Low Dose | Placebo |
|---|---|---|---|
| Baseline | 2.7 ± 1.96 | 2.4 ± 1.75 | 2.4 ± 1.49 |
| Change from Baseline at week 6 | -0.6 ± 2.00 | -1.2 ± 1.42 | -0.4 ± 1.60 |
The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer. An increase indicates an improvement (a greater volume of air expired).
| percentage of predicted FEV1 | MAP0010 High Dose | MAP0010 Low Dose | Placebo |
|---|---|---|---|
| Baseline | 74.8 ± 11.45 | 73.8 ± 13.10 | 65.9 ± 7.22 |
| Change from Baseline at 6 weeks | 6.3 ± 9.87 | 6.3 ± 7.73 | 5.9 ± 8.73 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MAP0010 High Dose | — | 0/69 (0%) | 21/69 (30.4%) |
| MAP0010 Low Dose | — | 0/67 (0%) | 10/67 (14.9%) |
| Placebo | — | 0/69 (0%) | 20/69 (29%) |
| Event | MAP0010 High Dose | MAP0010 Low Dose | Placebo |
|---|---|---|---|
| Upper Respiratory InfectionInfections and infestations | 8/69 | 6/67 | 12/69 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 7/69 | 2/67 | 5/69 |
| NasopharyngitisInfections and infestations | 6/69 | 2/67 | 3/69 |
The baseline characteristics are summarized on the Intent-to-treat population (those patients with at least 1 on treatment efficacy evaluation including 1 electronic diary entry).
| Age, Continuous(years) | MAP0010 High Dose | MAP0010 Low Dose | Placebo | Total |
|---|---|---|---|---|
| Mean | 10.2 ± 4.76 | 10.5 ± 4.75 | 10.2 ± 4.52 | 10.3 ± 4.68 |
| Sex: Female, Male(Participants) | MAP0010 High Dose | MAP0010 Low Dose | Placebo | Total |
|---|---|---|---|---|
| Female | 27 | 25 | 20 | 72 |
| Male | 41 | 40 | 45 | 126 |
The record gives a start of Jul 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide